Twenty-six strains of Aeromonas hydrophila isolated in cultured fish and soft-shelled turtles were collected from various areas of China. Their susceptibilities to 21 antibacterial agents were studied by disc diffusion method. It was showed that all strains tcsted were resistant to pcnieillin and cephalosporins. Most of the strains were sensitive to norfloxacin, chloramphenicol and furazolidone, but up to 73.1%, 70. 1% and 50. 0% of strains tested showed resistance to sulfonamides, aminogylcosides and tetracyclines respectively. Meanwhile, their susceptibilities were examined by micro-dilution procedure against 8 commonly used antibacterials including ampicillin, furazolidone, teltracycline, oxytetracyeline ,steptomycin, chloramphenicol, sulfonamides and ciprofloxacin. Only two of 26 strains of A. hydrophila were sensitive to all drugs tested except ampicillin. The remaining 24 strains were resistant to various combinations of 8 drugs. Majority of the strains carried a marker of resistance to 2～3 drugs and highly sensitive to ciprofloxacin and chloramphenicol. The results indicated that A. hydrophila was highly resistant to most of common antibioties in China and more new antibacterials should be introduced into aquaculture to control ever-increasing fish diseases. The criterion for drug resistant bacteria was also discussed in this paper.

Twenty six strains of Aeromonas hydrophila isolated in cultured fish and soft shelled turtles were collected from various areas of China. Their susceptibilities to 21 antibacterial agents were studied by disc diffusion method. It was showed that all strains tcsted were resistant to pcnieillin and cephalosporins. Most of the strains were sensitive to norfloxacin, chloramphenicol and furazolidone, but up to 73.1%, 70.1% and 50.0% of strains tested showed resistance to sulfonamides, aminogylcosides and tetracyclines respectively. Meanwhile, their susceptibilities were examined by micro dilution procedure against 8 commonly used antibacterials including ampicillin, furazolidone, teltracycline, oxytetracyeline ,steptomycin, chloramphenicol, sulfonamides and ciprofloxacin. Only two of 26 strains of A. hydrophila were sensitive to all drugs tested except ampicillin. The remaining 24 strains were resistant to various combinations of 8 drugs. Majority of the strains carried a marker of resistance to 2～3 drugs and highly sensitive to ciprofloxacin and chloramphenicol. The results indicated that A. hydrophila was highly resistant to most of common antibioties in China and more new antibacterials should be introduced into aquaculture to control ever increasing fish diseases. The criterion for drug resistant bacteria was also discussed in this paper.

Objective To evaluate the diagnostic value of 18F-FDG PET/CT in patients with pancreatic neoplasm.Methods Fifty-three patients (36 males,17 females; age:(60.3±8.9) years) who underwent 18F-FDG PET/CT examination for suspected pancreatic tumor were retrospectively analyzed.Thirtytwo of them underwent dual-time point imaging.The characteristics of PET/CT images and serum CA19-9 were reviewed.Pathological results were used as a gold standard for evaluating the diagnostic value of PET/CT.Two-sample t test,paired t test and ROC curve analysis were used for data analysis.Results Thirtynine patients were finally diagnosed with pancreatic cancer and the other fourteen patients with benign disease.With SUVmax cutoff value of 3.13,the sensitivity and specificity of single-time point 18F-FDG PET/CT for diagnosis of pancreatic cancer were 92.3％ (36/39) and 9/14,respectively.The SUVmax was significant different between pancreatic cancer group and benign disease group (6.16±2.89 vs 3.37± 1.58; t =4.46,P＜0.01).Combined with the level of CA19-9,the diagnostic sensitivity and specificity were 69.2％ (27/39)and 13/14,respectively.The SUVmax of the early scan (5.45±2.43) was significantly different from that of the delayed scan (6.87±2.93) in pancreatic cancer group (t =8.25,P＜0.01),whereas no difference could be found in the benign group (3.18±1.28 vs 4.18±2.49; t=2.24,P＞0.05).With the SUVmax cutoff value of 3.3,the sensitivity,specificity and accuracy in the early scan were 87.0％ (20/23),6/9 and 81.2％ (26/32),respectively.While with the SUVmax cutoff value of 3.0,the sensitivity,specificity and accuracy in the delayed scan were 95.7％ (22/23),5/9 and 84.4％ (27/32),respectively.Conclusion 18 F-FDG PET/CT is a useful tool in the differential diagnosis of benign from malignant pancreatic diseases.

ObjectiveTo investigate the efficacy and safety of camrelizumab monoclonal antibody combined with molecular-targeted therapy in elderly patients with unresectable or advanced hepatocellular carcinoma （HCC）. MethodsA retrospective analysis was performed for the patients with unresectable/advanced HCC who attended six hospitals from January 1， 2019 to March 31， 2021， and all patients received camrelizumab monoclonal antibody treatment， among whom 84.8% also received targeted therapy. According to the age of the patients， they were divided into elderly group （≥65 years） and non-elderly group （<65 years）. The two groups were assessed in terms of overall survival （OS）， progression-free survival （PFS）， objective response rate （ORR）， disease control rate （DCR）， and immune-related adverse events （irAE）. The chi-square test or the Fisher’s exact test was used for comparison of categorical data between groups； the independent samples t-test was used for comparison of normally distributed continuous data， and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups. The Kaplan-Meier method was used for survival analysis， and the log-rank test was used for comparison of survival curves. Univariate and multivariate Cox proportional hazards regression analyses were used to determine the independent influencing factors for PFS and DCR at 6 months. ResultsA total of 99 HCC patients were enrolled， with 27 in the elderly group and 72 in the non-elderly group. The elderly group had an OS rate of 67.8%， an ORR of 44.4%， and a DCR of 74.1% at 12 months and a median PFS of 6.4 （95% confidence interval ［CI］： 3.0‍ ‍—‍ ‍12.4） months， with no significant differences compared with the non-elderly group （all P>0.05）. The median OS was unavailable for the elderly group， while the non-elderly group had an OS of 18.9 （95%CI： 13.0‍ ‍—‍ ‍24.8） months； there was no significant difference between the two groups （P=0.485）. The univariate and multivariate Cox regression analyses showed that major vascular invasion （MVI） was an independent risk factor for PFS （hazard ratio ［HR］=2.603， 95%CI： 1.136‍ ‍—‍ ‍5.964， P=0.024） and DCR （HR=3.963， 95%CI： 1.671‍ ‍—‍ ‍9.397， P=0.002） at 6 months， while age， sex， etiology of HBV infection， presence of extrahepatic metastasis， Child-Pugh class B， and alpha-fetoprotein>400 ng/mL were not associated with PFS or DCR at 6 months. For the elderly group， the incidence rates of any irAE and grade 3/4 irAE were 51.9% and 25.9%， respectively， with no significant differences compared with the non-elderly group （P>0.05）， and skin disease was the most common irAE in both groups （39.4%）. ConclusionCamrelizumab monoclonal antibody combined with molecular-targeted therapy has similar efficacy and safety in patients with unresectable/advanced HCC aged ≥65 years and those aged <65 years. MVI is associated with suboptimal response to immunotherapy and poor prognosis.